SCHEMBL6319856

SCHEMBL6319856

CC1(C)[C@H](CC(=O)O)[C@@H]1c1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.42
ITGAV P06756 2/20 0.42
ITGB5 P18084 1/20 0.42
ITGB6 P18564 1/20 0.42
CA2 P00918 2/20 0.37
CAMK2A Q9UQM7 1/20 0.37
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 2/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ESR2 Q92731 3/20 0.35
MIF P14174 1/20 0.35
ESR1 P03372 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPK1 P28482 1/20 0.33
SLC9A1 P19634 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA3 P07451 1/20 0.32
TYR P14679 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326443 1.00 ITGB3 (0.42) ITGB3ITGAVITGB5ITGB6CA2
SCHEMBL6321357 1.00 ITGB3 (0.42) ITGB3ITGAVITGB5ITGB6CA2
SCHEMBL6325205 0.82 ITGB3 (0.47) ITGB3ITGAVITGB5ITGB6CA2
SCHEMBL6324394 0.82 ITGB3 (0.47) ITGB3ITGAVITGB5ITGB6CA2
SCHEMBL6324398 0.82 ITGB3 (0.47) ITGB3ITGAVITGB5ITGB6CA2
SCHEMBL6326524 0.79 ITGB3 (0.42) ITGB3ITGAVITGB5ITGB6CA2
SCHEMBL6317159 0.79 ITGB3 (0.42) ITGB3ITGAVITGB6CA2CAMK2A
SCHEMBL6324815 0.77 ITGB3 (0.53) ITGB3ITGAVITGB5ITGB6ALDH1A1
SCHEMBL8345029 0.68 CYP1A2 (0.36) ITGB3ITGAVITGB5ALDH1A1KDM4E
SCHEMBL6318635 0.65 ITGB3 (0.46) ITGB3ITGAVITGB5ITGB6CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921767-B2 Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives PHARMACIA CORPORATION (US) 2005-07-26 US disclosed
EP-1501830-A1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES Actelion Pharmaceuticals Ltd. (CH) 2005-02-02 EP disclosed
US-20040092538-A1 Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives PHARMACIA CORPORATION 2004-05-13 US disclosed
WO-2003093267-A1 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092538-A1 Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives ITGA5, ITGB5, ITGB3 ITGB3 3/4885ITGAV 6/4885ITGB5 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.